An interesting update on the ProtecT trial (NCT02044172) was given by Freddie Hamdy, MBChB, LRCSPEd, LRCSEd, LRCPSGlasg, FRCSEd, MD, FRCSEd(Urol), FRCS, FMedSci, of the University of Oxford, Oxford, UK, at the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK. The ProtecT trial was a randomized Phase III trial that compared three interventions for patients with localized prostate cancer: radical prostatectomy, radiation therapy or active monitoring. Dr Hamdy discusses the study design and presents the findings from the 10-year median follow-up.
10-year follow-up: the most effective treatment to ProtecT patients with localized prostate cancer?
